On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
We are very excited to launch our new website! Please take a few moments to click around and explore...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...